Physician profile
Charles Cottrell
NPI 1811911829
$8,723.69
in general payments reported to CMS, 2019-2025
37 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $374 · 2021: $1,253 · 2022: $1,539 · 2023: $1,703 · 2024: $1,468 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,769.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,811.95 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $910.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $632.49 | 2019-2025 | Xifaxan |
| Celgene Corporation | $508.97 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $358.63 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $323.10 | 2020-2023 | |
| Olympus America INC. | $286.20 | 2020-2023 | Evis Exera Lll Colonovideoscope, Endoclot Phs |
| Phathom Pharmaceuticals, INC. | $259.82 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $240.04 | 2019-2025 | Ocaliva |
| Pfizer INC. | $219.38 | 2019-2025 | |
| Ardelyx, INC. | $218.88 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $168.47 | 2021-2023 | Manoscan |
| Daiichi Sankyo INC. | $165.62 | 2019-2023 | Injectafer |
| Janssen Biotech, INC. | $160.97 | 2019-2024 | Stelara, Tremfya |
| Braintree Laboratories, INC. | $157.12 | 2021-2025 | Suflave, Sutab |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $150.98 | 2020-2022 | |
| Intuitive Surgical, INC. | $125.54 | 2025 | |
| Lilly USA, LLC | $107.47 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $106.75 | 2021-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $104.95 | 2022-2025 | Rebyota |
| Madrigal Pharmaceuticals | $102.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $101.52 | 2022-2024 | Dupixent |
| Genzyme Corporation | $81.37 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.15 | 2021 | |
| Aimmune Therapeutics, INC. | $65.64 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $63.66 | 2019 | |
| Ironwood Pharmaceuticals, INC | $37.53 | 2021 | |
| Gilead Sciences, INC. | $30.00 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $29.72 | 2023-2024 | Idacio |
| Axonics, INC. | $24.50 | 2022 | |
| Enterra Medical, INC. | $19.52 | 2023 | |
| Pharmacosmos Therapeutics INC. | $18.66 | 2022 | |
| Amgen INC. | $18.40 | 2021 | |
| Celltrion USA INC. | $13.53 | 2025 | Vegzelma |
| Otsuka America Pharmaceutical, INC. | $12.59 | 2019 | |
| Allergan, INC. | $11.06 | 2019 | |
| Vivus LLC | $8.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cottrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.